신경병증성 통증 시장 규모, 점유율 및 동향 분석 보고서 : 약제 클래스별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Neuropathic Pain Market Summary

The global neuropathic pain market size was estimated at USD 8.53 billion in 2025 and is projected to reach USD 15.23 billion by 2033, growing at a CAGR of 7.58% from 2026 to 2033. The neuropathic pain market was primarily driven by the rising global burden of chronic diseases, particularly diabetes and cancer, which significantly increased the prevalence of nerve damage related pain conditions.

Diabetic peripheral neuropathy remained the largest contributor, supported by the steady growth of diabetic populations in emerging economies such as India and China. For instance, in April 2025, Nature Publishing Group published a study indicating that approximately 50% of diabetes patients developed neuropathy, with prevalence ranging from 6% to over 60%. Painful diabetic peripheral neuropathy affected 13% to 35% of patients, with prevalence at 13.3% in diabetes, 8.7% in impaired glucose tolerance, 4.2% in impaired fasting glucose, and 1.2% in normal glucose tolerance. In addition, in October 2024, Frontiers in Endocrinology analyzed 4,908 patients, identifying 1,627 cases, representing 33.2% prevalence, supporting expanding diagnosis and treatment demand globally.

Another key driver was the evolving treatment landscape, characterized by a shift toward safer, targeted, and non-opioid therapies. Regulatory pressure and rising awareness regarding opioid misuse reduced dependence on opioids, accelerating adoption of anticonvulsants and antidepressants. Topical and transdermal formulations gained traction due to localized action, improved safety, and better patient compliance. Pharmaceutical companies increasingly invested in novel mechanisms and combination therapies to enhance efficacy and minimize side effects. Neuromodulation technologies such as spinal cord stimulation and transcutaneous electrical nerve stimulation further expanded treatment options. For instance, in January 2025, ScienceDirect reported neuropathic pain prevalence between 3% and 17%, with global estimates around 7% to 8%. Despite available therapies, treatment outcomes remained moderate, with many patients experiencing inadequate relief and increased healthcare utilization, reinforcing demand for more effective and innovative therapeutic solutions in the market.

Market growth was further supported by improvements in healthcare infrastructure, reimbursement frameworks, and drug accessibility, particularly across emerging regions. Countries in Asia Pacific and the Middle East experienced rising healthcare expenditure, expanding insurance coverage, and increased availability of cost-effective generic medications, improving patient access to neuropathic pain treatments. The growth of online pharmacies and digital health platforms enhanced drug distribution and patient adherence, especially for chronic conditions requiring long-term management. Government initiatives targeting non-communicable diseases also contributed to improved diagnosis and treatment rates. In addition, strategic collaborations between pharmaceutical companies and healthcare providers strengthened patient education and disease management practices. These developments collectively reduced treatment gaps, increased therapy penetration, and supported sustained market expansion. As healthcare systems continued to modernize and awareness improved, the neuropathic pain market experienced steady growth across both developed and developing regions globally.

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuropathic pain market report based on drug class, indication, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Anticonvulsants
• Antidepressants
• Opioids
• Topical Agents
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Diabetic Peripheral Neuropathy
• Postherpetic Neuralgia
• Chemotherapy-Induced Peripheral Neuropathy
• HIV-Associated Neuropathy
• Trigeminal Neuralgia
• Central Neuropathic Pain
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Topical
• Injectable
• Transdermal
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Institutional & Specialty Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Neuropathic Pain Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Neuropathic Pain Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 4.4. Anticonvulsants
  • 4.4.1. Anticonvulsants Market, 2021 - 2033 (USD Million)
• 4.5. Antidepressants
  • 4.5.1. Antidepressants Market, 2021 - 2033 (USD Million)
• 4.6. Opioids
  • 4.6.1. Opioids Market, 2021 - 2033 (USD Million)
• 4.7. Topical Agents
  • 4.7.1. Topical Agents Market, 2021 - 2033 (USD Million)

Chapter 5. Neuropathic Pain Market: Indication Business Analysis

• 5.1. Indication Market Share, 2025 & 2033
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 5.4. Diabetic Peripheral Neuropathy
  • 5.4.1. Diabetic Peripheral Neuropathy Market, 2021 - 2033 (USD Million)
• 5.5. Postherpetic Neuralgia
  • 5.5.1. Postherpetic Neuralgia Market, 2021 - 2033 (USD Million)
• 5.6. Chemotherapy-Induced Peripheral Neuropathy
  • 5.6.1. Chemotherapy-Induced Peripheral Neuropathy Market, 2021 - 2033 (USD Million)
• 5.7. HIV-Associated Neuropathy
  • 5.7.1. HIV-Associated Neuropathy Market, 2021 - 2033 (USD Million)
• 5.8. Trigeminal Neuralgia
  • 5.8.1. Trigeminal Neuralgia Market, 2021 - 2033 (USD Million)
• 5.9. Central Neuropathic Pain
  • 5.9.1. Central Neuropathic Pain Market, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Neuropathic Pain Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2021 - 2033 (USD Million)
• 6.5. Topical
  • 6.5.1. Topical Market, 2021 - 2033 (USD Million)
• 6.6. Injectable
  • 6.6.1. Injectable Market, 2021 - 2033 (USD Million)
• 6.7. Transdermal
  • 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)

Chapter 7. Neuropathic Pain Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
• 7.7. Institutional & Specialty Centers
  • 7.7.1. Institutional & Specialty Centers Market, 2021 - 2033 (USD Million)

Chapter 8. Neuropathic Pain Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Neuropathic Pain Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Neuropathic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly and Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Johnson & Johnson
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Novartis AG
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Viatris Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Teva Pharmaceutical Industries Ltd.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. AbbVie Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Grunenthal GmbH
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Daiichi Sankyo Company, Limited
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives